Cythemias
News
Team reports new method to identify immune cells
Photo by Graham Colm A new method for identifying immune cells could pave the way for rapid detection of hematologic malignancies from a small...
News
Drug appears feasible for hard-to-treat myelofibrosis
myelofibrosis Results of a phase 2 study suggest the JAK2/FLT3 inhibitor pacritinib is a feasible treatment option for patients with...
News
EC approves drug for polycythemia vera
Image courtesy of AFIP The European Commission (EC) has approved ruxolitinib (Jakavi) to treat adults with polycythemia vera (PV) who are...
News
Inhibitor outperforms BAT in myelofibrosis trial
Image by Peter Anderson Results of a phase 3 trial suggest the JAK2/FLT3 inhibitor pacritinib may be more effective for patients with...
News
Order of mutations impacts MPN behavior
essential thrombocythemia The order in which genetic mutations are acquired determines how myeloproliferative neoplasms (MPNs) behave, according...
News
Ruxolitinib bests standard treatment for PV
In patients who could not tolerate or were resistant to hydroxyurea, ruxolitinib proved superior to standard therapy for controlling hematocrit...
News
CHMP recommends ruxolitinib for PV
Credit: Zak Hubbard The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is recommending the approval of...
News
Iron overload aids potentially deadly bacteria
Credit: Paul A.
News
CRISPR bests TALEN in iPSCs
Credit: Salk Institute The gene-editing technology CRISPR can precisely and efficiently alter human stem cells, according to research published...
News
Teams map paths to drug resistance in cancers, MPNs
Researchers say they’ve discovered key events that prompt drug resistance in myeloproliferative neoplasms (MPNs) and certain solid tumor...
Conference Coverage
Combo may enhance spleen reductions in MF
the 2014 ASH Annual Meeting SAN FRANCISCO—Combination therapy with ruxolitinib and panobinostat shows signs of efficacy in myelofibrosis (MF),...